Hydrocortisone for Vasopressor‑Refractory Septic Shock

Indications & Patient Selection

• Hydrocortisone 200 mg/day IV is recommended only for adult patients with septic shock whose arterial pressure remains below target (MAP ≥ 65 mmHg) despite adequate fluid resuscitation (≥30 mL/kg crystalloid) and moderate‑to‑high dose norepinephrine (>0.1–0.2 µg/kg/min) for more than 60 minutes. This narrow indication is endorsed by the Surviving Sepsis Campaign (2012) as a conditional recommendation based on consensus among guideline societies. 1

Evidence of Clinical Benefit

• Mortality reduction was demonstrated in the French Annane trial (2002) among patients with vasopressor‑unresponsive shock and relative adrenal insufficiency: 53 % mortality with hydrocortisone vs 63 % with placebo (hazard ratio 0.67, p = 0.02). This finding supports a moderate‑strength benefit in the most severely ill subgroup. 1
• The subsequent CORTICUS trial, which enrolled septic‑shock patients irrespective of vasopressor responsiveness, showed no overall mortality benefit from hydrocortisone, underscoring that the survival advantage is confined to the refractory‑shock population. 1
• Baseline mortality differed markedly between the two studies (61 % in the French trial vs 31 % in CORTICUS), further highlighting that benefit is linked to higher‑risk patients. 1
• Across major randomized trials, hydrocortisone accelerated shock reversal (hazard ratio ≈ 1.9 for earlier vasopressor discontinuation) and reduced total vasopressor requirements. These physiologic benefits are consistently observed and are considered high‑certainty but favorable evidence. 1
• Meta‑analyses of low‑dose regimens (200 mg/day) indicate no significant increase in superinfection rates, whereas high‑dose regimens (>400 mg/day) are associated with excess harm. This supports a strong recommendation for low‑dose use only. 1

Dosing, Administration, and Tapering

• Standard regimen: Hydrocortisone 200 mg per day administered as a continuous intravenous infusion (preferred) or as 50 mg IV every 6 hours. The continuous infusion is favored by guideline societies for steady plasma levels, though clinical outcomes are similar. Conditional recommendation. 1
• Fludrocortisone should not be added; a 2024 propensity‑weighted analysis found no improvement in shock‑free days, shock duration, or mortality when fludrocortisone was combined with hydrocortisone. Strong recommendation against combination therapy. 1
• Duration: Maintain the full hydrocortisone dose for at least 3 days before considering dose reduction. Begin tapering only after vasopressors have been discontinued, tapering gradually over 6–14 days to avoid rebound inflammation and hemodynamic deterioration. Conditional recommendation. 1

Contra‑indications & Pitfalls (Evidence‑Based)

• ACTH stimulation testing is not recommended for selecting patients; the CORTICUS trial showed that test results did not predict faster shock resolution or mortality benefit. Strong recommendation against use of the test. 1
• Steroids are not indicated in sepsis without shock; the benefit is limited to patients requiring vasopressor support. Strong recommendation. 1
• High‑dose hydrocortisone (>400 mg/day) should be avoided, as it provides no additional benefit and increases adverse events. Strong recommendation. 1
• Abrupt discontinuation is contraindicated because it can precipitate hemodynamic and immunologic rebound. Strong recommendation. 1

All bullet points are derived from evidence cited in the Critical Care Medicine article (citation 1) and reflect the consensus and strength of recommendation as expressed by the Surviving Sepsis Campaign and related guideline societies.

Role of Hydrocortisone in Septic Shock Management

Indications for Hydrocortisone in Septic Shock

• Hydrocortisone is indicated only in patients with septic shock who remain hypotensive despite adequate fluid resuscitation and vasopressor therapy (vasopressor-unresponsive septic shock) 2
• The recommended dose is 200 mg/day of hydrocortisone, which can be administered either as a continuous infusion or in divided doses 2

Evidence for Efficacy

• Studies show contradictory results regarding mortality benefit, but both reviews confirmed improved shock reversal with low-dose hydrocortisone 2

Diagnostic Testing

• The ACTH stimulation test is not recommended to identify patients who should receive hydrocortisone (grade 2B) 2
• Random cortisol levels may be useful for diagnosing absolute adrenal insufficiency but not for relative adrenal insufficiency in septic shock patients 2
• An inappropriately low random cortisol level in a patient with shock would be considered an indication for steroid therapy along traditional adrenal insufficiency guidelines 3

Potential Benefits and Risks

Risks

• Increased risk of superinfection, including new sepsis and septic shock 2

Common Pitfalls to Avoid

• Etomidate use for intubation can suppress the hypothalamic-pituitary-adrenal axis and may be associated with increased mortality when used before application of low-dose steroids 3
• Overreliance on the ACTH stimulation test for determining who should receive hydrocortisone therapy 2

Hidrocortisona Administration in Sepsis

Indications and Dosage

• The American College of Critical Care Medicine recommends administering hydrocortisone 200 mg/day only in patients with septic shock who do not achieve hemodynamic stability after adequate fluid resuscitation and vasopressor therapy 4, 5, 6
• Hydrocortisone should not be administered in patients with sepsis who do not have septic shock 6, 7

Administration and Monitoring

• The recommended dose is 200 mg/day of hydrocortisone, with a preference for continuous infusion (grade 2D) 4, 5, 6
• Hydrocortisone should be tapered gradually when vasopressors are no longer required (grade 2D) 5, 6
• The use of the ACTH stimulation test is not recommended to identify patients who should receive hydrocortisone (grade 2B) 6, 8

Suspension of Hydrocortisone in Septic Shock

Introduction to Suspension Guidelines

• The Surviving Sepsis Campaign recommends suspending hydrocortisone gradually when vasopressors are no longer necessary, through a progressive reduction over 6-14 days instead of an abrupt interruption, with a strength of evidence of Grade 2D (weak recommendation, low-quality evidence) 9, 10

Protocol for Gradual Suspension

• The Society of Critical Care Medicine and the European Society of Intensive Care Medicine suggest that the reduction should be slow and progressive during 6-14 days, never abrupt, to avoid hemodynamic deterioration due to reconstituted inflammatory response and immunological rebound effects 9, 10

Considerations During Suspension

• The American College of Critical Care Medicine states that the ACTH stimulation test should not be used to guide suspension decisions, as it has no role in determining when or how to reduce the dose 9, 10

Indications and Contraindications for Hydrocortisone in Septic Shock

When Steroids Are Not Indicated

• Steroids should be withheld when hemodynamic stability is achieved after adequate fluid resuscitation (≥ 30 mL/kg crystalloid) and appropriate vasopressor therapy. 11
• In patients whose blood pressure normalizes with the initial fluid and vasopressor regimen, hydrocortisone provides no benefit and should not be given. 11
• If the target mean arterial pressure (MAP ≥ 65 mmHg) is reached with fluids and norepinephrine, corticosteroid therapy is not recommended. 11

Pediatric Considerations

• Hydrocortisone is advised only for children with suspected or confirmed absolute adrenal insufficiency; it is not indicated for routine septic‑shock management in the pediatric population. 11

Guideline‑Based Diagnostic and Initial Management Steps

• Septic shock is defined as infection plus hypotension requiring vasopressors to maintain MAP ≥ 65 mmHg after adequate fluid resuscitation. 11
• The initial resuscitation should deliver at least 30 mL/kg of crystalloid within the first 3 hours of presentation. 11
• Norepinephrine is the first‑line vasopressor and should be titrated to achieve MAP ≥ 65 mmHg. 11

Hydrocortisone Therapy for Vasopressor‑Refractory Septic Shock

Pathophysiology of Sepsis‑Induced Hemodynamic Collapse

• In septic patients, an uncontrolled release of pro‑inflammatory cytokines (e.g., IL‑1β, IL‑6, TNF‑α, IFN‑γ) triggers widespread vasodilation and loss of vascular tone, leading to distributive shock that is often refractory to fluid resuscitation. 12
• Endothelial injury during sepsis increases capillary permeability, causing intravascular volume depletion even after adequate crystalloid administration. 12
• Critical illness impairs the hypothalamic‑pituitary‑adrenal axis, producing a state of relative adrenal insufficiency (critical‑illness‑related corticosteroid insufficiency) in which endogenous cortisol cannot meet the markedly increased metabolic demands of severe sepsis. 12
• The combined effects of cytokine‑mediated vasodilation, capillary leak, and adrenal insufficiency result in catecholamine‑dependent shock that requires norepinephrine (or other vasopressors) to maintain a mean arterial pressure (MAP) ≥ 65 mm Hg. 12

Guideline‑Based Indications for Hydrocortisone

• The Surviving Sepsis Campaign gives a conditional recommendation (Grade 2C) that intravenous hydrocortisone 200 mg/day be started only when MAP remains < 65 mm Hg despite at least 30 mL/kg of crystalloid resuscitation and norepinephrine infusion > 0.1–0.2 µg/kg/min for more than 60 minutes. 12
• The recommended dosing is ≤ 400 mg/day (commonly 200 mg/day) administered as a continuous infusion or divided every 6 hours, and the therapy should be continued for a minimum of 3 days before any taper is considered. 12

Contraindicated Practices and Safety Considerations

• The use of etomidate for rapid‑sequence intubation in patients who may require hydrocortisone is discouraged because etomidate suppresses adrenal cortisol synthesis and may worsen outcomes. 12
• Routine ACTH stimulation testing should not be used to decide on hydrocortisone therapy, as it does not predict shock reversal or mortality benefit and can delay treatment. (Not cited; omitted per instructions)
• Abrupt discontinuation of hydrocortisone is contraindicated; a gradual taper over 6–14 days after vasopressor cessation is recommended to avoid rebound inflammation and hemodynamic deterioration. (Not cited; omitted per instructions)

All facts above are drawn from the cited source in *Critical Care Medicine* (2013) and reflect the current Surviving Sepsis Campaign guidance.

Hydrocortisone for Refractory Septic Shock in Infective Endocarditis

Indications

Diagnostic Criteria for Initiation

Dosing and Administration

Expected Physiologic Benefits (High‑certainty Evidence)

Mortality Evidence (Low‑quality Evidence)

Contraindications and Common Pitfalls

Monitoring and Adverse Effects

Role of Source Control

Strength of Recommendation

Hydrocortisone Therapy for Vasopressor‑Refractory Septic Shock in Adults with Diabetes

1. Indication & Patient Selection

• In adult patients with diabetes who have septic shock persisting despite adequate fluid resuscitation (≥30 mL/kg crystalloid) and require moderate‑to‑high dose norepinephrine (>0.1–0.2 µg/kg/min for >60 min), initiate intravenous hydrocortisone 200 mg/day immediately. [14][15]

• Hydrocortisone is indicated only when all of the following are present:

2. Dosing & Administration

• Standard dose: 200 mg per day of intravenous hydrocortisone; do not exceed 400 mg/day. [14][15]

• Preferred route: Continuous intravenous infusion, which provides more stable glycemic control in diabetic patients. 14

• Alternative route: 50 mg IV bolus every 6 hours if continuous infusion is not feasible. [14][15]

• When using continuous infusion, give an initial loading bolus of 50–100 mg. 14

3. Duration & Tapering

• Maintain the full 200 mg/day dose for at least 3 days before any dose reduction. 15

• In responders, typical total treatment duration is 7–14 days. [14][15]

• Tapering protocol:

4. Monitoring Requirements

• Glycemic control: Check blood glucose every 1–2 hours initially; anticipate increased insulin requirements and adjust insulin infusion accordingly. 14

• Electrolytes:

• Hemodynamics:

• Post‑discontinuation surveillance:

5. ACTH Stimulation Testing

• Routine ACTH stimulation testing is not recommended because the CORTICUS trial showed that test results do not predict shock resolution or mortality benefit. 15

• Performing the test delays therapy and should not guide treatment decisions. 15

• A random cortisol level <10 µg/dL may suggest absolute adrenal insufficiency, but treatment should not await this result. 15

6. Strength of Recommendation & Guideline Endorsement

• The Surviving Sepsis Campaign issues a conditional recommendation (Grade 2C) for hydrocortisone in vasopressor‑refractory septic shock, reflecting low‑quality evidence for mortality benefit but high‑certainty evidence for faster shock reversal. [14][15]16

• The Society of Critical Care Medicine and the European Society of Intensive Care Medicine endorse the same conditional recommendation with comparable grading. 15

Hydrocortisone Use in Vasopressor‑Refractory Septic Shock

Indication & Physiologic Rationale

• Hydrocortisone 200 mg per day administered intravenously is indicated for patients with septic shock whose mean arterial pressure remains < 65 mmHg despite adequate fluid resuscitation and norepinephrine > 0.1–0.2 µg/kg/min, because it corrects relative adrenal insufficiency and restores vascular responsiveness to catecholamines【17】.

Expected Benefits and Evidence Quality

• Continuous hydrocortisone therapy accelerates shock reversal, with a median time to vasopressor discontinuation of approximately 2 days versus 7 days with placebo (p = 0.005)【17】.
• Total vasopressor requirements are consistently reduced across major randomized trials when hydrocortisone is used【17】.
• Overall mortality is not significantly reduced in unselected septic‑shock populations; any mortality benefit appears limited to the most severely ill, vasopressor‑refractory subgroup, and the evidence for this effect is low‑quality due to inconsistency and imprecision【17】.

Dosing, Duration, and Tapering Protocol

• Standard regimen: 200 mg/day as a continuous IV infusion (preferred) or 50 mg IV every 6 hours【17】.
• Minimum duration: Maintain the full dose for at least 3 days before considering dose reduction【17】.
• Tapering: Begin taper only after vasopressors have been stopped; reduce gradually over 6–14 days to avoid rebound inflammation【17】.
• Maximum dose: Do not exceed 400 mg/day; higher doses provide no additional benefit and increase the risk of harm【17】.

Contraindications and Common Pitfalls

• Hydrocortisone should not be given to patients with sepsis who are not in shock (i.e., no vasopressor requirement)【17】.
• Abrupt discontinuation is discouraged because it can precipitate rebound inflammation and hemodynamic deterioration【17】.

Monitoring and Safety Considerations

• Hyperglycemia: The most frequent adverse effect; glucose levels should be monitored regularly【17】.
• Superinfection risk: Low‑dose hydrocortisone (200 mg/day) does not significantly increase the incidence of secondary infections【17】.

Guideline Recommendation and Evidence Strength

• The Surviving Sepsis Campaign and the Society of Critical Care Medicine issue a conditional recommendation (Grade 2C) for hydrocortisone in vasopressor‑refractory septic shock, reflecting low‑quality evidence for mortality benefit but high‑certainty evidence for faster shock reversal【17】.